scholarly journals Venous Thromboembolism Prophylaxis in Cancer Patients

10.5772/31717 ◽  
2012 ◽  
Author(s):  
Hikmat Abdel-Razeq
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Thromboembolism Prophylaxis ◽  
Venous Thromboembolism Prophylaxis

Venous Thromboembolism Prophylaxis for Medical Service—Mostly Cancer—Patients at Hospital Discharge

2011 ◽  
Vol 124 (12) ◽  
pp. 1143-1150 ◽  
Author(s):  
John Fanikos ◽  
Amanda Rao ◽  
Andrew C. Seger ◽  
Gregory Piazza ◽  
Elaine Catapane ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Hospital Discharge ◽  
Medical Service ◽  
Thromboembolism Prophylaxis ◽  
Venous Thromboembolism Prophylaxis

scholarly journals Venous thromboembolism and prophylaxis in cancer patients

Medicina ◽  
2008 ◽  
Vol 44 (3) ◽  
pp. 175 ◽  
Author(s):  
Saulius Paškauskas ◽  
Juozas Pundzius ◽  
Giedrius Barauskas
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Central Venous Access ◽  
Prognostic Index ◽  
Factor V Leiden ◽  
Endothelial Damage ◽  
Factor V ◽  
Thromboembolism Prophylaxis ◽  
Common Cause ◽  
Venous Thromboembolism Prophylaxis

Venous thromboembolism is a serious complication in patients with cancer. The seriousness of venous thromboembolism as a complication in cancer patients is becoming recognized as an important medical issue. Venous thromboembolism is a multifactorial disease associated with vascular endothelial damage, stasis of blood flow, and hypercoagulation. Preexisting morbidity, mutations of factor V Leiden or prothrombin 20210A, type of cancer, presence of metastases, use of central venous access, surgery, anesthesia, etc., increase the risk of venous thromboembolism. The patients with malignancies have a 7-fold increase in the risk of venous thromboembolism compared with individuals without cancer. Venous thromboembolism is the second most common cause of mortality in cancer patients. Venous thromboembolism is the most common cause of death at 30 days after surgery in patients undergoing surgery for cancer. Venous thromboembolism caused death in 46.3% of the cases after surgery for cancer. The Geneva prognostic index identified predictive factors for an adverse outcome, and the American College of Chest Physicians (ACCP) has suggested the guidelines for the prevention of venous tromboembolism in cancer patients. Cancer patients should receive appropriate venous thromboembolism prophylaxis. The methods used for venous thromboembolism prophylaxis are mechanical, pharmacological, or a combination of both. Well-timed thromboprophylaxis may protect patients from venous thromboembolism, early lethal outcome and even influence survival.

Cancer related venous thromboembolism - prophylaxis and therapy

VASA ◽  
2014 ◽  
Vol 43 (4) ◽  
pp. 245-251 ◽  
Author(s):  
Thomas Gary
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Malignant Disease ◽  
Treatment Guidelines ◽  
High Rate ◽  
Anticoagulant Treatment ◽  
Thromboembolism Prophylaxis ◽  
Venous Thromboembolism Prophylaxis ◽  
Venous Thromboembolic ◽  
Impact On Survival

Cancer is a highly thrombophilic entity leading to a high rate of symptomatic and even asymptomatic venous thromboembolic (VTE) events in patients suffering from malignant disease. As VTE events have impact on survival and can be reduced significantly by anticoagulant treatment, guidelines on prophylaxis of these events by means of anticoagulation exist from various societies. Purpose of this review is to give a concise overview of current possibilities for prophylaxis and also for the therapy of VTE events in cancer patients.

scholarly journals Venous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients

2017 ◽  
Vol 22 (3) ◽  
pp. 71-102 ◽  
Author(s):  
Tomasz Urbanek ◽  
Zbigniew Krasiński ◽  
Maciej Kostrubiec ◽  
Wojciech Sydor ◽  
Piotr Wysocki ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Surgical Patients ◽  
Thromboembolism Prophylaxis ◽  
Venous Thromboembolism Prophylaxis

scholarly journals Are There Any Differences in the Clinical and Economic Outcomes Between US Cancer Patients Receiving Appropriate or Inappropriate Venous Thromboembolism Prophylaxis?

2009 ◽  
Vol 5 (4) ◽  
pp. 159-164 ◽  
Author(s):  
Alpesh N. Amin ◽  
Jay Lin ◽  
Guiping Yang ◽  
Stephen Stemkowski
Keyword(s):  
At Risk ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Economic Outcomes ◽  
Thromboembolism Prophylaxis ◽  
Venous Thromboembolism Prophylaxis ◽  
Patients At Risk

Prophylaxis is often underused and inappropriately prescribed. This study compares the efficacy and cost of appropriate and partial prophylaxis in cancer patients at risk for VTE.

Sign in / Sign up

Export Citation Format

Share Document